1 
 
FRIEND PK PRE -FRIEND PROTOCOL V. 2.1                                           
JUNE 29, 2021  
  
 
 
 
 
Pharmacokinetics and hepatic safety of EGCG  
 
 
 
Protocol Leader: Ayman Al -Hendy  MD PhD, University of Illinois at 
Chicago  
Data and Coordination Leader: Hepi[INVESTIGATOR_254220], PhD, Yale University  
 
Version 2.1 
 
 
 
 
National Clinical Trial (NCT) Identified Number:  [STUDY_ID_REMOVED]  
IND 150951  
 
 
Funded by : [CONTACT_254240] (NICHD)  
 
  
2 
 
FRIEND PK PRE -FRIEND PROTOCOL V. 2.1                                           
JUNE 29, 2021  
  
Prepared by:  
[CONTACT_254241]  
[ADDRESS_309140]  [ZIP_CODE]  
 
(203) 785 -5185  
 
[EMAIL_4905]  
 
Last updated:  June 29 , 2021  
 
 
 
 
 
 
 
 
 
  
3 
 
FRIEND PK PRE -FRIEND PROTOCOL V. 2.1                                           
JUNE 29, 2021  
 Protocol Subcommittee  
 
Group email address:  
 
Member Name  [CONTACT_254285] -Hendy,  MD, PhD  [EMAIL_4906]  
 
Frank Gonzalez, MD  frgz12@uic. edu 
 
James Segars, MD  [EMAIL_4907]  
  
Hugh Taylor, MD  [EMAIL_4908]  
  
Hepi[INVESTIGATOR_254220], PhD  [EMAIL_4909]  
 
4 
 
FRIEND PK PRE -FRIEND PROTOCOL V. 2.1                                           
JUNE 29, 2021  
 Table of Contents  
1 ACRONYMS  ................................ ................................ ................................ ................................ .................  1 
2 STUDY SYNOPSIS  ................................ ................................ ................................ ................................ ....... 2 
2.1 OBJECTIVES  ................................ ................................ ................................ ................................ .....................  2 
2.2 PATIENT POPULATION  ................................ ................................ ................................ ................................ ...... 2 
2.3 STUDY DESIGN  ................................ ................................ ................................ ................................ .................  2 
2.4 TREATMENT  ................................ ................................ ................................ ................................ .....................  2 
2.5 PRIMARY OUTCOME PARAMETER  ................................ ................................ ................................ ....................  3 
2.6 SECONDARY OUTCOME PARAMETERS ................................ ................................ ................................ ..............  3 
2.7 STATISTICAL ANALYSIS  ................................ ................................ ................................ ................................ ... 3 
2.8 ANTICIPATED TIME OF COMPLETION  ................................ ................................ ................................ ...............  4 
2.9 REGULATORY COMPLIANCE  ................................ ................................ ................................ .............................  4 
3 BACKGROUND AND SIGNIFICANCE  ................................ ................................ ................................ .... 5 
3.1 OVERVIEW  ................................ ................................ ................................ ................................ .......................  5 
3.2 EGCG  (GREEN TEA EXTRACT ) AND UTERINE FIBROIDS ................................ ................................ ...................  5 
3.3 EGCG  CLINICAL TRIAL IN WOMEN WITH SYMPTOMATIC UTERINE FIBROIDS  ................................ ....................  6 
4 OBJECTIVES ................................ ................................ ................................ ................................ ................  8 
4.1 PRIMARY AIM ................................ ................................ ................................ ................................ ..................  8 
4.2 SECONDARY AIM ................................ ................................ ................................ ................................ .............  8 
4.3 TREATMENT DESIGN , STUDY POPULATION , AND STUDY SUMMARY  ................................ ................................  8 
4.3.1  Treatment Design  ................................ ................................ ................................ ................................ ....... 8 
4.3.2  Study Population  ................................ ................................ ................................ ................................ ........  8 
4.3.3  Study Summary  ................................ ................................ ................................ ................................ ...........  8 
4.3.4  Inclusion Crit eria ................................ ................................ ................................ ................................ ..... 10 
4.3.5  Exclusion Criteria  ................................ ................................ ................................ ................................ .... 10 
4.3.6  Study Termination Criteria  ................................ ................................ ................................ .......................  11 
4.4 RISK/BENEFIT ASSESSMENT  ................................ ................................ ................................ ...........................  [ADDRESS_309141] benefits to participants.  ................................ ................................ ................................ ...........................  11 
4.4.2 Possible risks/discomforts  ................................ ................................ ................................ ........................  11 
5 STUDY DESIGN  ................................ ................................ ................................ ................................ .........  13 
5.1 TYPE OF DESIGN  ................................ ................................ ................................ ................................ ............  13 
5.2 RATIONALE FOR DESIGN  ................................ ................................ ................................ ................................  13 
5.3 RECRUITMENT  ................................ ................................ ................................ ................................ ................  13 
5.4 INFORMED CONSENT  ................................ ................................ ................................ ................................ ...... 13 
5.5 RANDOMIZATION /TREATMENT INITIATION  ................................ ................................ ................................ .... 14 
5.6 PHYSICAL EXAM ................................ ................................ ................................ ................................ ............  14 
5.7 TRANSVAGINAL ULTRASOUND EXAM ................................ ................................ ................................ ............  14 
5.8 LABORATORY EXAM ................................ ................................ ................................ ................................ ...... 14 
5.9 SCHEDULE OF EVALUATIONS  ................................ ................................ ................................ .........................  15 
6 DATA ANALYSIS  ................................ ................................ ................................ ................................ ...... 16 
6.1 DATA ANALYSIS  ................................ ................................ ................................ ................................ ............  16 
6.2 PRIMARY OUTCOME MEASUREMENTS  ................................ ................................ ................................ ...........  16 
6.3 SECONDARY OUTCOME MEASUREMENTS  ................................ ................................ ................................ ...... 16 
6.4 DIFFERENCE IN SERUM FOLATE LEVELS AMONG WILDTYPE MTHFR,  MTHF R (C677T),  AND MTHFR  
(A1298C)  PATIENTS .  STATISTICAL ANALYSES  ................................ ................................ ................................ ............  16 
7 TECHNICAL ASPECTS  ................................ ................................ ................................ ............................  17 
7.1 STUDY AGENT PREPARATION  ................................ ................................ ................................ ........................  17 
7.2 CONCOMITANT MEDICATIONS  ................................ ................................ ................................ .......................  17 
5 
 
FRIEND PK PRE -FRIEND PROTOCOL V. 2.1                                           
JUNE 29, 2021  
 7.3 ADVERSE EXPERIENCE REPORTING  ................................ ................................ ................................ ................  17 
7.3.1  Adverse Events  ................................ ................................ ................................ ................................ ..........  17 
7.3.2  Classification of an Adverse Event  ................................ ................................ ................................ ...........  17 
7.3.3  Time Period and Frequency for Event Assessment and Follow -up ................................ ..........................  19 
7.3.4  Adverse Event Reporting  ................................ ................................ ................................ ..........................  19 
7.3.5  Serious Adverse Event Reporting  ................................ ................................ ................................ .............  20 
7.4 UNANTICIPATED PROBLEMS ................................ ................................ ................................ ...........................  21 
7.4.1  Definition of Unanticipated Problems (UP)  ................................ ................................ .............................  21 
7.4.2  Unanticipated Problem Reporting  ................................ ................................ ................................ ............  21 
7.5 DATA COLLECTION AND MANAGEMENT (INCLUDING QUALITY ASSURANCE /COMPLIANCE MEASURES ) .........  [ADDRESS_309142]  ................................ ................................ ................................ ...... 23 
7.8 REPORTING  ................................ ................................ ................................ ................................ ....................  23 
7.9 OBLIGA TION OF THE INVESTIGATOR  ................................ ................................ ................................ ..............  24 
7.10 REGULATORY REQUIREMENTS  ................................ ................................ ................................ .......................  24 
7.11 PROTOCOL AMENDMENTS  ................................ ................................ ................................ ..............................  24 
7.12 OVERALL POLICY  ................................ ................................ ................................ ................................ ...........  24 
7.13 MAIN STUDY  ................................ ................................ ................................ ................................ ..................  25 
7.13.1  Major Publications  ................................ ................................ ................................ ................................ ... 25 
7.13.2  Minor Publications  ................................ ................................ ................................ ................................ ... 26 
7.13.3  Ancillary Study  ................................ ................................ ................................ ................................ .........  27 
7.13.4  Related Publications  ................................ ................................ ................................ ................................ . 27 
7.13.5  Outside Studies  ................................ ................................ ................................ ................................ .........  27 
7.13.6  Presentations  ................................ ................................ ................................ ................................ ............  28 
8 REFERENCES  ................................ ................................ ................................ ................................ ............  29 
9 APPENDIX J: INVESTIGATOR SIGNATURE [CONTACT_254286]  ................................ ...............................  30 
9 APPENDIX K: DSMB CHARTER  ................................ ................................ ................................ ...........  [ADDRESS_309143]  
 HIPAA  Thyroid -Stimulating Hormone  
 TSH  
Health Related Quality of Life  HRQL  Total and Free Testosterone  
 T, FT  
Human Chorionic Gonadotropin  
 hCG  Ultrasound  
 U/S 
Human Investigation 
Committee  HIC World Health Organization  
 WHO  
Identification  ID   
[ADDRESS_309144] a randomized clinical trial to determine the  
pharmacokinetics and hepatic safety of epi[INVESTIGATOR_99907] (EGCG).     
 
MTHFR represents the most studied enzyme in the folate pathway with strong evidence that 
polymorphisms decrease enzyme activity. Because of the potential effect of EGCG on folate 
metabolism possibly leading to folate depletion, MTHFR represents a clinically relevant target. 
We are planning to stratify subjects by [CONTACT_254242], MTHFR (C677T), and MTHFR  
(A1298C). The prevalence of MTHFR mutations can range from 30 to 40% in  the American 
population for C677T and ~50% for A1298C. We will evaluate if green tea catechins may have 
modulating properties that may increase the risk of folic acid depletion in women expressing 
known MTHFR polymorphisms. In this protocol we will evalua te if polymorphisms related to 
folate metabolism increase the risk for folate depletion in women receiving green tea extract.  
2.[ADDRESS_309145] of 36 women  ages ≥18 to ≤40 years (at time of consent) . Eighteen 
women will have in tramural and/or subserosal fibroids  and 18 women will be without i ntramural 
fibroids and/or subserosal fibroids . Participants  will be recruited over approximately a 6-month  
period from the FRIEND Collaborative clinical sites (Johns Hopkins University, Univ ersity of 
Illinois at Chicago, University of Chicago and Yale University ). 
2.3 Study Design  
Randomization will be stratified by [CONTACT_654] (age 18 -29, 30 -40) and presence of fibroids.  The 
randomization scheme will be coordinated through the data coordination center ( DCC).  
2.4 Treatment  
The 36 women  will be randomized to one of the following groups:  
1. EGCG daily alone . 
2. EGCG daily with clomiphene citrate  100mg  for [ADDRESS_309146] and  pelvic ultrasound will also be performed after 
informed consent.  Patient will be given the EGCG (Green Tea extract) to start after the screening 
visit.  Patients will be counseled on die tary restrictions while on EGCG.  
3 
 
FRIEND PK PRE -FRIEND PROTOCOL V. 2.1                                           
JUNE 29, 2021  
  
Visit 1 will occur on menstrual cycle day 3 ± 2 days.  EGCG levels over 8 hours, liver function, 
and urine pregnancy testing will occur at this visit. Patients will be assigned into their groups and 
provided with their res pective treatments at this visit.  
 
Patient will return between days 8 -10 of the cycle for Visit 2.  EGCG levels over 8 hours , liver 
function, estrogen, and urine pregnancy testing will occur at this visit.   
 
The patient will return for Visit 3 between days 14 -16 for a pelvic ultrasound evaluation of 
endometrial thickness and ovarian characteristics.  
 
The final study visit (Visi t 4) will be approximately [ADDRESS_309147] and pi[INVESTIGATOR_10685].   
 
The 4 lab panels (screening, Visits 1, 2, and 4) will include EGCG and metabolite analyses, liver 
panel (AST, ALT, total bilirubin, ALP) and estrogen levels, and a urine pregnancy test.  The EGCG 
analyses at visits 1 and 2 will include testing over 8 hours.  
2.5 Primary Outcome  Parameter  
The primary outcome  parameter will be differences in p harmacokinetic parameters of EGCG and 
the major metabolites between the 3 groups . 
 
2.6 Secondary Outcome  Parameters  
The secondary outcome  parameters will include : 
• Changes in liver function between the 3 groups . 
• Changes in estrogen  levels (E2) between the 3 groups.  
• Changes in endometrial thickness and ovarian characteristics between the 3 groups.  
• Change in the pharmacokinetic parameters of EGCG and metabolites  within each 
group.  
• Difference in serum folate levels among wildtype MTHF R, MTHFR (C677T), and 
MTHFR (A1298C) patients.   
2.[ADDRESS_309148] deviation, median, interquartile range of 
the level of the pharmacokinetic parameters of EGCG and 2 of the major metabolites at different 
time points and the difference from screening to Visit 1 , Visit 2 or Visit 4,  and the changes in liver 
function, estrogen levels, endometrial thickness , and follicular measurements  will be presented for 
the three treatment groups, and then stratified by [CONTACT_254243]/or the presence or absence of 
uterine fibroid. For comparison, a two -way ANOVA will be used to compare the  effects of the 
three treatments and the presence of fibroids on the above outcome para meters. With a sample size 
of 36  patients  for the three treatment groups, which includes 18  subjects with uterine fibroids and 
18 without uterine fibroids, with an alpha of 0.05, the power of the study would be 0. 44 and 0. 85 
for a medium (0.25) or large (0.4) effect size, respectively. There are insufficient preliminary data 
[ADDRESS_309149] sizes. For the 
comparison of serum folate levels among wildtype MTHFR, MTHFR (C677T), and MTHFR 
(A1298C) patients , ANOVA (unadjusted) and multivariate linea r regression will be used.   
2.8 Anticipated Time of Co mpletion  
We estimate  the study will take approximately 6-12 months  to complete.  Participants will be 
recruited from each of the 4 participating FRIEND sites .  
2.9 Regulatory Compliance  
The DCC is working with The Eunice Kennedy Shriver National Institute of Child Health and 
Human Development (NICHD), the three participating FRIEND institutions, and the single 
Institutional Review Board  (Johns Hopkins University ) to ensure that clinical study data and 
regulatory requirements are met regarding the Food and Drug  Administration (FDA) code for 
federal regulations.  This trial is registered on http://www.clinicaltrials.gov  (NCT 04177693 ). 
5 
 
FRIEND PK PRE -FRIEND PROTOCOL V. 2.1                                           
JUNE 29, 2021  
 3 Background and Significance  
3.1 Overview  
Uterine leiomyomas (fibroids) affect 30 -50% of reproductive -age women and are a significant 
cause of infertility. Intramural and submucosal fibroids reduce the likelihood of pregnancy 
(RR=0.3 -0.7) compared to unaffected women.  Surgical removal of fibroids  can restore fertility; 
however, recurrence rates are high, and benefits are often temporary.  Importantly, serious 
postoperative consequences such as adhesions can adversely affect a woman’s fertility and health 
in general.  Hormonal therapi[INVESTIGATOR_254221], but these therapi[INVESTIGATOR_254222].  There is a critical need for effective, non -
hormonal, non -surgical fertility treatment options for women with fibroids that may distort the 
uterine cavity. Our long -term goal is to develop novel non -hormonal treatments for uterine 
fibroids. Green Tea leaves contain polyphenols and catechins, such as epi[INVESTIGATOR_99907] 
(EGCG). Studies from our group and others have shown that EGCG is the most abundant an d 
active compound responsible for effects of Green Tea extracts.  Notably, EGCG can be taken 
during pregnancy and there are no known teratogenic effects. EGCG polyphenols inhibit key 
pathways of tumor growth by [CONTACT_254244] l proliferation, 
transformation, inflammation, apoptosis, metastasis and invasion. Prior to initiating a 
randomized, double -blind, multi -center, prospective, clinical trial of EGCG versus placebo  in 
women with uterine fibroids to evaluate birth rate a phar macokinetic and hepatic safety analysis 
must be conducted.  The pharmacokinetics and hepatic safety of EGCG with clomiphene citrate 
and letrozole are unknown. A 3 -arm study will be conducted in women with and without fibroids 
to allow comparisons between th ese groups. The results of this study will be used to confirm 
hepatic safety for the larger multi -center FRIEND study.  
  
3.2 EGCG (Green Tea extract) and Uterine fibroids  
Green Tea leaves contain polyphenols such as catechins or flavin -3-ols that include epic atechin  
(EC) , epi[INVESTIGATOR_27145]  (EGC) , epi[INVESTIGATOR_99907] (EGCG), and alkaloids.  Catechins are the 
major components of tea phenols and constitute about 30 -42% of the dry weight of Green Tea. 
Studies have shown that the EGCG catechin is the most abunda nt and active compound responsible 
for most of Green Tea’s role in promoting good health and accounts for the favorable research 
result cited in the medical literature with the use of Green Tea extracts. EGCG have the highest 
level of polyphenols and makes  it the major anti -oxidant agent in Green Tea. A study conducted 
by [CONTACT_254245] -neoplastic 
effects against a wid e range of human tumor cells (4 ) EGCG polyphenol have been shown to 
inhibit key pathways of tumor growth. EGCG appears to block each stage of tumorigenesis by 
[CONTACT_254246], transformation, inflammation, 
apoptosis, o xidative stress and invasion (4 ). Studies by [INVESTIGATOR_21026] -Hendy et al d emonstrated increasing 
levels of Catechol -O-methyl transferase (COMT) in uterine leiomyoma compared to adjacent 
myometrium and described its important role  in fibroid pathogenesis (5 ) Beside various useful 
antioxidant and anti -inflammatory effects, EGCG ex erts a potent COMT inhibitor effect which 
also contribute to effective anti -fibroid action (2, 5 ). Additionally, published work by [INVESTIGATOR_124]. Al -
Hendy also demonstrated the utility of EGCG for inhibiting fibroid tumor formatio n in vivo in 
nude mouse model (3 ). [CONTACT_254290]-Hendy’s research team (a member of this consortium) has reported 
that EGCG acting as anti -uterine fibroid agent through the modulation of multiple signal 
6 
 
FRIEND PK PRE -FRIEND PROTOCOL V. 2.1                                           
JUNE 29, 2021  
 transduction pathways.  The group demonstrated that EGCG works on the gene level, to inhibit 
the proliferation of Human fibroi d cells and induces apoptosis (2 ). This study also showed an 
impressive 14 -fold increase in the expression of the BMP2 gene in EGCG -treated human fibroid 
cells than in the untreated control (2 ). That major increase in the secr etion of BMP2 from fibroids 
by [CONTACT_254247] -induced endometrial BMP -resistance 
through increased binding to the BMP receptors which will lead to improvement in the 
decidualization of the endometrium and subsequen tly enhancement of implantation, fertility and 
pregnancy outcomes.  Furthermore, studies also demonstrated that EGCG significantly decreased 
TGF -β3 production by [CONTACT_254248]. As TGF -β3 is the main cytokine responsible for 
endometrial BMP -resistance , such effect of EGCG would be expected to lead to improved 
endometrial receptivity.  
3.3 EGCG Clinical trial in women with symptomatic uterine fibroids  
To  translate  the  positive  EGCG  anti -fibroid  preclinical  findings  in  human  fibroid  cell  lines  
and  fibroid  animal  models, the efficacy and safety of EGCG on uterine fibroids burden and 
quality of life in women with symptomatic uterine  fibroids  were  evaluated in  an  NIH -funded  
double -blinded,  placebo -controlled  randomized  clinical  trial(NCT  01311869) (1). A total of 39 
reproductive -age women (age 18 –50 years, day 3 serum follicle -stimulating hormone  <12  IU/L)  
with  symptomatic  uterine  fibroids  were  recruited  for  this  study.  All subjects had at least one 
fibroid lesion 2 cm3 or lar ger in volume, as confirmed by [CONTACT_254249]. The subjects were randomized to oral daily treatment with either 800 mg of 
decaffeinated EGCG  or placebo  (800  mg  of  brown  rice)  for  4  months,  and  uterine  fibroid  
volumes  were  measured  at  the  end  of  study,  also  by  [CONTACT_254250].  The  fibroid -specific  symptom  severity  and  HRQL  of  these  uterine  fibroid  
patients  were  scored at each monthly visit, using the symptom s everity and quality -of-life   
questionnaires   (1).   Of   the   final   39   women   recruited for the study, 33 completed all five 
visits of the study. In  the  placebo  group  (n  =  11),  fibroid  volume  increased  (24.3%) over the 
study period; howev er, patients randomized to  green  tea  extract  treatment  (n  =  22)  showed  
significant  reduction (32.6%, P = 0.0001) in total uterine fibroids volume.  In  addition,  EGCG  
treatment  significantly  reduced  fibroid -specific  symptom  severity  (32.4 %,  P =  0.0001)  and  
induced significant improvement in HRQL (18.53%, P = 0.01) compared   to   the   placebo   group.   
Anemia   also   significantly  improved  by  0.7  g/dL  (P =  0.02)  in  the  EGCG  treatment   group,   
while   average   blood   lo ss   significantly decreased (P =  0.001).  No adverse effects, endometrial 
hyperplasia, or other endometrial pathology were observed in either group (1).  
 
 
 
 
 
 
 
 
 
 
 
 
 
7 
 
FRIEND PK PRE -FRIEND PROTOCOL V. 2.1                                           
JUNE 29, 2021  
 Figure 1. Flowchart  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
Visit 2: Lab visit  Screening, Consent, Enrollment  
Visit 1: Labs, randomization, clomiphene 
citrate/letrozole dispensing,  
Visit 3: Pelvic ultrasound  
Visit 4: Lab panel and return 
unused medications  
[ADDRESS_309150] of 36 women with  or without uterine  
fibroids, age ≥18 to ≤40 ye ars (at time of consent).  
 
The appropriate study candidates will be recruited from the clinics of the 4 FRIEND Collaborative 
sites after obtaining informed written consent from the female subjects .  Recruited participant s 
will meet the inclusion and exclusion criteria detailed below.  Monitoring of this trial at all sites 
will be conducted by [CONTACT_254251] .   
4.3.2 Study Population  
Thirty -six (36) patients will be equally randomized via computer -generated randomization 
schedule to receive:  
1. Two capsules of decaffeinated Green Tea extract (close to 800mg EGCG)  taken orally on 
a daily basis for up to [ADDRESS_309151] taken orally on a daily basis for up to 2 
months with clomiphene citrate 100mg for 5 days  
3. Two capsules) of decaffeinated Green Tea extract taken orally on a daily basis for up to 2 
months with letrozole 5mg for 5 days.  
4.3.3 Study Summary   
 
Recruitment and Prescreening: see Section 5 descriptions following.  
 
 
 
-30      0      +30 
 
 
 Menstrual Cycle 1  Menstrual Cycle 2  
Day 30 -
35 visit  Screening  Day 1 -5 
visit Day 14 -
16 visit  Day 8 -
10 visit  

9 
 
FRIEND PK PRE -FRIEND PROTOCOL V. 2.1                                           
JUNE 29, 2021  
  
 
Screening visit (anytime in cycle 1) :  
1. Obtain informed, signed consent . 
2. Complete medical /gynecological/menstrual  history and physical exam of female study 
participant.  
• Vital signs, height, weight, hip and abdominal circumference, BMI  
• Pap smear if necessary per cur rent ACOG time -frame guidelines  
• Standard pelvic and brea st exam conducted by [CONTACT_254252] 12 months  
 
3. Perform radiological exams.  
• Pelvic ultrasound measuring uter ine and ovarian characteristics or within past 3  months  
 
4. Laboratory tests: EG CG and metabolites, liver function, folate, estrogen levels, genetics  
    sample collection and urine pregnancy test.  
 
5. Dispense Green Tea extract and educate on dietary restrictions while taking Green Tea extract  
    and with the importance of taking food. All patients to start Green Tea extract at this visit.  
 
6. Contraception education. Patients will be counseled to use non -hormonal double -barrier  
    method: a male/female condom plus spermicidal agents, cervica l cap, diaphragm or sponge.  
 
7. Concomitant medication collection.  
 
Visit 1 (Day 1 -5): 
Patient will be seen on menstrual cycle day 3 ± 2 days for clomiphene citrate/letrozole initiation 
visit  
 
1. Vital signs and weight.  
2. Laboratory tests: EGCG levels over 8 hours (0.5,1,2,4,6,8),liver function, folate, estrogen 
level, and urine pregnancy testing.  
3. Concomitant medication collection and pi[INVESTIGATOR_254223].  
4. Randomization and dispensation of clomiphene citrate/letrozole.  
5. Contraception education.  Patients will be  counseled to use non -hormonal double -barrier 
method: a male/female condom plus spermicidal agents, cervical cap, diaphragm or 
sponge.  
 
Visit 2 (day 8-10): 
Patient will return several days after final clomiphene citrate/letrozole administration  
 
1. Vital sign s and weight.  
2. Laboratory tests: EGCG levels over 8 hours (0.5,1,2,4,6,8), liver function, folate, estrogen 
level and urine pregnancy testing.  
10 
 
FRIEND PK PRE -FRIEND PROTOCOL V. 2.1                                           
JUNE 29, 2021  
 3. Concomitant medication collection and pi[INVESTIGATOR_254224].  
4. Cont raception education . Patients will be counseled to use non -hormonal double -barrier 
method: a male/female condom plus spermicidal agents, cervical cap, diaphragm or 
sponge.  
Visit 3 (day 14 -16): 
 
1. Pelvic ultrasound via a transvaginal probe  or transabdominal transducer  evaluation of 
endometrial thickness and ovarian characteristics.  
 
Visit 4 (day 30 -35): 
Patient will return for final study visit.  
  
1. Vital signs and weight, hip and abdominal circumference, BMI  
2. Laboratory tests: EGCG and metabolit es, liver function, estrogen level, folate, and urine  
    pregnancy  
    test. 
3. Concomitant medication collection. Return unused medications and pi[INVESTIGATOR_254225].  
 
Future Studies:  One tube of blood will be collected at each visit to be stored for fut ure analyses 
related to this study.   
4.3.4 Inclusion Criteria  
1. Healthy women ≥18 to ≤[ADDRESS_309152] use a double -barrier method for contraception  
4.3.5 Exclusion Criteria  
1. Subjects using Green Tea/EGCG within 2 weeks prior to stud y enrollment. Matcha 
(Japanese green tea), maca powder, green tea beverages and all other forms of green tea 
require a 2 -week wash -out. Patients with a detectable EGCG level at the screening visit 
will be excluded.  
2. Known liver disease (defined as AST or AL T>2 times normal, or total bilirubin >2.5 
mg/dL).   
3. History of alcohol abuse (defined as >14 drinks/week) or binge drinking of ≥ 6 drinks at 
one time).   
4. Subject using hormonal contraceptives: 3 -month wash -out is required for all oral or cyclic 
progestins, GnRH agonists/ antagonists, gonadotropi[INVESTIGATOR_2115], injectable contraceptives, oral 
contraceptives, contraceptive implants and previous use of clomiphene and letrozole.  
5. Subjects who are pregnant or breastfeeding  
6. Known hypersensitivity to the study drugs  
7. Any chronic disease  
11 
 
FRIEND PK PRE -FRIEND PROTOCOL V. 2.1                                           
JUNE 29, 2021  
 4.3.6 Study Termination Criteria  
Any serious adverse event considered to be related to study treatment (see section [IP_ADDRESS] and 
7.3.5) will be considered reason for termination of assigned intervention; participant will be 
followed up for cy cle outcome and will contribute research data towards intent -to-treat analyses. 
This includes allergic reactions and liver toxicity.  Women with elevation in liver function test with 
3 times the upper limit of normal will be terminated from the study and wi ll return to site for repeat 
testing every 48 hours until resolution.  
 
 
All reports of liver toxicity will be reviewed by [CONTACT_4318] (see section 7.3.4). If three (3) or 
more trial participants developed active liver disease, as defined below, this would be an 
unexpected significant risk requiring trial termination:  
  
1. Alanine aminotransferase (ALT) or Aspartate aminotransferase (AST) ≥ 8 x upper limit 
of normal (ULN)  
2. ALT or AST ≥ [ADDRESS_309153] and total bilirubin (TBL) > [ADDRESS_309154] or International 
Normalized Ratio (INR) > 1.[ADDRESS_309155] > [ADDRESS_309156] with appearance of fatigue, nausea, vomiting, right upper 
quadrant pain or tenderness, fever, rash, and/or eosinophilia (> 5%).  
 
4.4 Risk/Benefit Assessment  
4.4.[ADDRESS_309157] benefits to participants.    
4.4.2 Possible risks/discomforts  
Blood draws: Discomfort, bruising, infection or bleeding at the needle puncture site  
Pelvic ultrasound: abdominal or pelvic discomfort  
EGCG: Gastrointestinal upset; rare liver toxicity. The literature supports a p otential relationship 
between high -dose Green Tea extract consumption and transient changes in serum liver enzymes.  
Rare (<5%) and transient liver transaminase elevations have been documented. Hepatotoxicity 
tended to show a temporal relationship between Green Tea extract consumption and effect onset 
with Green Tea extract -induced toxicity mainly manifesting after roughly [ADDRESS_309158] or EGCG was administered under fasted conditions, while 
exposure to Green Tea under fed conditions appears to alleviate such risk.  
Clomiphene Citrate: Visual chang es (such as blurring of vision, double vision, floaters), abdominal 
pain, nausea, vomiting, constipation, mood changes, headache, hot flashes, fatigue, abnormal 
endometrial thickening, multiple pregnancies, formation of ovarian cyst, breast discomfort, 
abnormal uterine bleeding, and bloating  
Letrozole: Fatigue, dizziness, nausea, hot flashes, arthritis pain in your joints, back pain, increased 
cholesterol levels, formation of ovarian cysts, multiple pregnancies  
12 
 
FRIEND PK PRE -FRIEND PROTOCOL V. 2.1                                           
JUNE 29, 2021  
 Other risks: There is also the risk of loss of  confidentiality.  Filling  out the  questionnaire s may make 
the subjects uncomfortable  or feel some anxiety.  There  is a risk that information about  the subject 
may become known  to people  outside  of this study.  
As this is a NIH (NICHD) funded study, your study information is protected by a Certificate of 
Confidentiality. This Certificate allows us, in some cases, to refuse to give out your information 
even if requested using legal means.  
It does not protect information that we have to report by [CONTACT_2371], such a s child abuse or some infectious 
diseases. The Certificate does not prevent us from disclosing your information if we learn of 
possible harm to yourself or others, or if you need medical help.  
Disclosures that you consent to in this document are not protec ted. This includes putting research 
data in the medical record or sharing research data for this study or future research. Disclosures 
that you make yourself are also not protected.  
 
 
 
  
13 
 
FRIEND PK PRE -FRIEND PROTOCOL V. 2.1                                           
JUNE 29, 2021  
 5 Study Design            
5.1 Type of Design  
This will be a randomized, open -label, multi -center, pharmacokinetics and hepatic safety  trial of 
EGCG with 36 total patients in 3 treatment arms . The randomization scheme will be coordinated 
through the DCC and the randomization will be stratified for age groups 18 -29 and 3 0-40 and 
presence of uterine fibroids .   
5.2 Rationale for Design  
The pharmacokinetics and hepatic safety of EGCG with clomiphene citrate and letrozole are 
unknown.  A 3 -arm study will be conducted in women with and without fibroids to allow 
comparisons between these grou ps.  The results of this study will be used to confirm hepatic 
safety for the larger multi -center FRIEND study. The pharmacokinetics and hepatic safety of 
EGCG with clomiphene citrate and letrozole are unknown. A 3 -arm study will be conducted in 
women with  and without fibroids to allow comparisons between these groups. The results of this 
study will be used to confirm hepatic safety for the larger multi -center FRIEND study.  
 
5.3 Recruitment  
Hospi[INVESTIGATOR_307]/Local Health Care Referrals  
Subjects will be recruited at each site from individual practice(s) as well as faculty/resident clinics.   
 
Local Advertisements  
Advertisements will be placed in local newspapers and will be continued on a regular basis if 
response is good.   
 
IRB Approval   
It is expressly acknowledged that all informational material that could be construed to be 
advertising will be approved by [CONTACT_254253].  
5.[ADDRESS_309159] been identified, they will be referred to the site  clinical coordinator or his/her 
designee.  The clinical protocol will be explained to potential subjects by [CONTACT_254254].  Inclusion and exclusion criteria will 
be reviewed.  After t he study has been completely explained, they will be given the infor med 
consent documents to review.  Some individuals may wish to complete the informed consent 
process at the time of this discussion.  In these cases, the informed consent documents will be 
signed once all questions are resolved.  In other cases, the subjects may wish to take the consent 
forms home for further consideration.  In these cases, the coordinator will set up a tentative 
timeframe to be back in touch with the subjects.  The consents  can be signed either with the 
coordinator or with a physician once all questions have been answered to the satisfaction of the 
potential patient.  A signed informed consent document, approved by [CONTACT_254255], 
will be confirmed on all subjects  prior to the baseline evaluation.  In order to be eligible for 
enrollment and randomization, all inclusion and exclusion criteria must be met .   
14 
 
FRIEND PK PRE -FRIEND PROTOCOL V. 2.1                                           
JUNE 29, 2021  
 5.5 Randomization/Treatment Initiation  
Thirty -six (36) patients will be equally randomized via computer -generated  randomization 
schedule to receive: 1) 800  mg  of  decaffeinated  EGCG  taken  orally  on  a  daily  basis  with 
food  for  up  to  2  month s;  2) 800  mg  of  decaffeinated  EGCG  taken  orally  on  a  daily  basis  
with food  for  up  to  2  month s with cl omiphene citrate  100mg for 5 days; 3) [ADDRESS_309160] diameter. Participants will be weighed while dressed 
in light clothing, without shoes. Weight will be collected at each cycle initiation visit; however, 
height, waist and hip circumferences are only collected at the screening and end of study drug 
visits. Blood pressure will be determined in the right arm in t he sitting position.  Large cuff will 
be used as necessary. Blood pressure will be assessed at each visit. Elevated blood pressures 
(≥160/100) will be repeated following acclimation to the study environment. All patients aged [ADDRESS_309161] these resolved prior to study entry.   
5.7 Transvaginal Ultrasound Exam  
An ultrasound  exam will be performed with a transvaginal probe. For subjects who cannot tolerate  
a transvaginal probe,  a transabdominal ultrasound evaluation will be performed.  The following 
measures will be obtained  at screening : uterine dimensions, leiomyoma prese nce and size, other 
uterine abnormalities, endometrial thickness, ovarian size in three dimensions, the size of the 
largest ovarian follicle, follicle count in the largest plane and ovarian morphology. Ovarian size is 
determined by [CONTACT_254256] [ADDRESS_309162].  Ovarian volume is 
determined  by [CONTACT_254257] a prolate ellipsoid (length x width x height x π/6) (Pache, Hop et al. 
1991) .  If the patient has had no prior test of tubal patency, this may be the desired time to perform 
a sonohysterogram to determine tubal patency.  Only endometrial thickness and ovarian follicular 
measurements will be measured at visit 2.  
5.[ADDRESS_309163]. Jeremy Johnson is the pharmacokinetics core leader for UICentre, the academic drug disc overy 
initiative at the University of Illinoi s at Chicago.      
Table 1. Screening labs of study women  
LOCAL LABORATORY BLOOD TESTS  CENTRAL  LABORATORY BLOOD TESTS  
15 
 
FRIEND PK PRE -FRIEND PROTOCOL V. 2.1                                           
JUNE 29, 2021  
 Hormones  Liver  EGCG and metabolites  
Estrogen  Total Bilirubin  EGCG  
 ALT/AST  EGC 
 Alkaline Phosphatase  ECG 
  4′-O-methyl -epi[INVESTIGATOR_254226] s related to folate metabolism  
 
5.9 Schedule of Evaluations  
 
Study  procedure  Cycle 1   Cycle 2  
  Screening  Visit 1 (Day 1 
-5) Visit 2 (Day 8 
-10) Visit 3 (Day 
14-16) Visit 4 (Day 
30 - 35) 
Informed consent  X        
Inclusion/exclusion 
criteria  X        
Demographic information  X        
Medical history  X        
Concomitant medications  X X X  X 
Gynecological history  X        
Menstrual history  X        
Vital signs and weight  X X X  X 
Height  X        
Hip and abdominal 
circumference  X       X 
Physical examination  X        
Pap smear  X*        
Pelvic and breast exam  X**        
Genetics sample, 
laboratory test  X     
 Pelvic ultrasound  Xǂ    X   
EGCG levels and 
metabolites, laboratory 
test X X X  
X 
Liver function, laboratory 
test X X X  X 
Folate, laboratory test  X      X 
Estrogen levels, laboratory 
test X X  X  X  
Contraceptive counseling  X X X    
Dispense EGCG  X        
Pi[INVESTIGATOR_254223]    X X  X 
Randomization and 
dispensation of 
clomiphene citrate or 
letrozole    X    
  
[ADDRESS_309164]  X X X  X 
*If necessary  per ACOG guidelines      
**if not done within past [ADDRESS_309165] 3 months       
6 Data Analysis            
6.1 Data Analysis  
Data will be collected prospectively by [CONTACT_254258], supervised 
by [CONTACT_7880].  Individual data will be entered into a web -based data management system created 
by [CONTACT_15791] , using only a study ID number.  
6.2 Primary Outcome Measurements  
The primary outcome  parameter will be differences in pharmacokinetic parameters of EGCG and 
2 of the major metabolites between the 3 treatment groups . 
6.3 Secondary Outcome Measurements  
The secondary outcome  parameters will include : 
• Changes in liver function between the 3 groups . 
• Changes in estrogen  levels  (E2) between the 3 groups.  
• Changes in endometrial thickness and ovarian characteristics between the 3 groups.  
• Change in the pharmacokinetic parameters of E GCG and metabolites  within each 
group.  
6.4 Difference in serum folate levels among wildtype MTHFR, MTHFR (C677T), and 
MTHFR (A1298C) patients.  Statistical Analyses  
Since the number of patients for this study is minimal and multiple factors are of concern , 
descriptive statistics will be used,  and the study is expected to be under powered to perform any 
formal statistical inference . The number, mean, standard deviation, median, interquartile range of 
the level of the pharmacokinetic parameters of EGC G and 2 of the major metabolites at different 
time points and the difference from  screening to Visit 1 or Visit 2 or Visit 4 , and the changes in 
liver function, hormone levels, endometrial thickness  and follicular measurements  will be 
presented for the th ree treatment groups, and then stratified by [CONTACT_254243]/or the presence or 
absence of uterine fibroid.  Patients with a detectable EGCG level at the screening visit will be 
excluded. For  comparison, a two -way ANOVA will be used to compare the  effects of the three 
treatments and the presence of fibroids on the above outcome parameters. With a sample size of 
36 patients  for the thre e treatment groups, and 1 8 subjects with uterine fibroids and 1 8 without 
uterine fibroids, with an alpha of 0.05, the power of the study would be 0. 44 and 0. 85 for a medium 
(0.25) or large (0. 4) effect size, respectively. There are insufficient preliminary data in the literature 
to support or not support the reasonableness of these effect sizes. For the comparison of serum 
folate levels among wildtype MTHFR, MTHFR (C677T), and MTHFR (A1298C) patients , 
ANOVA (unadjusted) and multivariate linea r regression will be used.   
  
[ADDRESS_309166] party tested for identity and poten cy to confirm compliance with Certificates of 
Authentication (COA).  The material per the COA has a shelf life of [ADDRESS_309167] holding 
conditions.  Clomiphene citrate and letrozole will be obtained through generic pharmaceutical 
companies.   
 
The study coordinator at each site will be responsible for distributing the supply drug kits, verifying 
pi[INVESTIGATOR_4382]/vial counts, and determining that there are adequate medication supplies for existing patients 
and new patients to be randomized.  The PI [INVESTIGATOR_254227].  
7.2 Concomitant Medications  
An inquiry into concomitant medications will be made at the screening visit as well as each 
subsequent visit.   
7.3 Adverse Experience Reporti ng 
7.3.1 Adverse Events  
[IP_ADDRESS]  Definition of Adverse Events (AE)  
Adverse event means any untoward medical occurrence associated with the use of an 
intervention in humans, whether or not considered intervention -related (21 CFR 312.32 (a)).  
[IP_ADDRESS]  Definition of Serious Adverse Events (SAE)  
An adverse event (AE) or suspected adverse reaction is considered "serious" if, in the view of 
either the investigator or sponsor, it results in any of the following outcomes: death, a life -
threatening adverse event, inpatient hospi[INVESTIGATOR_1081], a 
persistent or significant incapacity or substantial disruption of the ability to conduct normal life 
functions, or a congenital anomaly/birth defect. Important medical events that may not result in 
death, be l ife-threatening, or require hospi[INVESTIGATOR_708], based upon 
appropriate medical judgment, they may jeopardize the participant and may require medical or 
surgical intervention to prevent one of the outcomes listed in this definiti on.  
7.3.2 Classification of an Adverse Event  
[IP_ADDRESS]  Severity of Event  
The following guidelines will be used to describe severity.  
 
• Mild  – Events require minimal or no treatment and do not interfere with the participant’s 
daily activities.  
18 
 
FRIEND PK PRE -FRIEND PROTOCOL V. 2.1                                           
JUNE 29, 2021  
 • Moderate  – Events result in  a low level of inconvenience or concern with the therapeutic 
measures. Moderate events may cause some interference with functioning.  
• Severe  – Events interrupt a participant’s usual daily activity and may require systemic 
drug therapy or other treatment. Severe events are usually potentially life -threatening or 
incapacitating.  Of note, the term “severe” does not necessarily equate to “serious ”. 
[IP_ADDRESS]  Relationship to Study Intervention  
All adverse events (AEs) must have their relationship to study intervention assessed by [CONTACT_12288]/her 
clinical judgment. The degree of certainty about causality will be graded using the categories 
below. In a clinical trial, the study product must always be suspect.  
 
• Definitely Related – There is clear evidence to suggest a causal relationship, and other 
possible contributing factors can be ruled out. The clinical event, including an abnormal 
laboratory test result, occurs in a plausible time relationship to study intervention 
administration and cannot be explained by [CONTACT_113395]. The response to with drawal of the study intervention (dechallenge) should be 
clinically plausible. The event must be pharmacologically or phenomenologically 
definitive, with use of a satisfactory rechallenge procedure if necessary.  
• Probably Related – There is evidence to sugg est a causal relationship, and the influence 
of other factors is unlikely. The clinical event, including an abnormal laboratory test 
result, occurs within a reasonable time after administration of the study intervention, is 
unlikely to be attributed to con current disease or other drugs or chemicals, and follows a 
clinically reasonable response on withdrawal (dechallenge). Rechallenge information is 
not required to fulfill this definition.  
• Potentially Related – There is some evidence to suggest a causal rela tionship (e.g., the 
event occurred within a reasonable time after administration of the trial medication). 
However, other factors may have contributed to the event (e.g., the participant’s clinical 
condition, other concomitant events). Although an AE may r ate only as “possibly related” 
soon after discovery, it can be flagged as requiring more information and later be 
upgraded to “probably related” or “definitely related”, as appropriate.  
• Unlikely to be related – A clinical event, including an abnormal labor atory test result, 
whose temporal relationship to study intervention administration makes a causal 
relationship improbable (e.g., the event did not occur within a reasonable time after 
administration of the study intervention) and in which other drugs or c hemicals or 
underlying disease provides plausible explanations (e.g., the participant’s clinical 
condition, other concomitant treatments).  
• Not Related – The AE is completely independent of study intervention administration, 
and/or evidence exists that the event is definitely related to another etiology. There must 
be an alternative, definitive etiology documented by [CONTACT_15370].  
[IP_ADDRESS]  Expectedness  
The study PI [INVESTIGATOR_118631].  An 
AE will be considered  unexpected if the nature, severity, or frequency of the event is not 
consistent with the risk information listed in the package insert, or in the consent form.  
 
19 
 
FRIEND PK PRE -FRIEND PROTOCOL V. 2.1                                           
JUNE 29, 2021  
 7.3.3 Time Period and Frequency for Event Assessment and Follow -up 
The occurrence of an AE or seriou s adverse event (SAE) may come to the attention of study 
personnel during study visits and interviews of a study participant presenting for medical care, or 
upon review by a study monitor.  
All AEs including local and systemic reactions not meeting the crit eria for SAEs will be captured 
on the appropriate case report form (CRF). Information to be collected includes event description, 
time of onset, clinician’s assessment of severity, relationship to study product (assessed only by 
[CONTACT_254259] a diagnosis), and time of resolution/stabilization of 
the event. All AEs occurring while on study must be documented appropriately regardless of 
relationship. All AEs will be followed to adequate resolution.  
Any medical condition that is  present at the time that the participant is screened will be considered 
as baseline and not reported as an AE. However, if the study participant’s condition deteriorates 
at any time during the study, it will be recorded as an AE.  
Changes in the severity of an AE will be documented to allow an assessment of the duration of the 
event at each level of severity to be performed. AEs characterized as intermittent require 
documentation of onset and duration of each epi[INVESTIGATOR_1865].  
Site personnel will record all reporta ble events with start dates occurring any time after informed 
consent is obtained until 7 (for non -serious AEs) or 30 days (for SAEs) after the last day of study 
participation.  At each study visit, the investigator will inquire about the occurrence of AE/ SAEs 
since the last visit.  Events will be followed for outcome information until resolution or 
stabilization.  
7.3.[ADDRESS_309168] dose of study medication and reported to the DCC.  
Non-serious adverse events will be reported to the DSMB quarte rly.  
 
Supervising Institutional Review Boards (IRBs) will be notified by [CONTACT_254260]. Investigators also 
will notify the medical monitor and DCC within [ADDRESS_309169] (DSMB) as part of their safety review.  
 
The DCC will provide study -wide summary statistics (not filtered by [CONTACT_1570]) of adverse 
events to the single IRB annually and upon request to all sites on an annual basis for submission 
to their IRBs.  
20 
 
FRIEND PK PRE -FRIEND PROTOCOL V. 2.1                                           
JUNE 29, 2021  
 7.3.5 Serious Adverse Event Reporting  
All serious adverse events (SAEs) that occur from randomization through  thirty days after the 
last dose of study medication must be reported or if the patient is pregnant, 6 weeks following 
delivery.  
 
The site PI [INVESTIGATOR_254228] [available in the “Study Form s” section of the FRIEND website], and then emailing the 
document in PDF format to  [EMAIL_4905] . Subjects will be identified by [CONTACT_254261].  No other ide ntifying information will be included on the form. The site PI [INVESTIGATOR_254229], and if it 
is related, possibly related, or unrelated to participation in the research. The site coordi nator will 
enter the information into the DCC  database.  The DCC will inform the sIRB within 24 hours of 
after knowledge of a SAE.  
 
The Safety Surveillance team, consisting of the DCC and lead PI [INVESTIGATOR_87031], will analyze the 
SAE to determine if it meet s the criteria listed in the OHRP 45CFR46 and/or FDA 21CFR312.32 
& 3.14.80.  
 
These determinations will dictate timeframes for sites’ submission to the DCC, and the DCC’s 
submission to the DSMB ( Table 2): 
 
Table 2. Types of Serious Adverse Events and their reporting requirements  
TYPE  SITE DCC 
Unanticipated and 
related/possibly related SAE, 
fatal or life -threatening  Report to DCC within 1 
business day of discovery  
 Notify DSMB by [CONTACT_254262]/possibly related SAE  Report to DCC within 1 
business day of discovery  Notify DSMB 5 business 
days of receiving site report  
Anticipated and 
related/possibly related SAE  Report to DCC within 5 
business days of discovery  Notify DSMB 5 business 
days of receiving site report  
Unrelated SAE (anticipated or 
unanticipated  Report to DCC within 10 
business days (no more than 
3 weeks) of  discovery  Notify DSMB within 10 
business days (no more than 
3 weeks) of receiving site 
report  
 
Upon receiving notification of an SAE, the DSMB will review it via a closed -session email or 
conference -call discussion.  The DSMB will send a report to the DC C within two weeks; reports 
for life -threatening SAEs will be submitted in one week. The DSMB report will include: statement 
indicating what related information the DSMB reviewed; the review date; the DSMB’s assessment 
of the information reviewed; and the DSMB’s recommendation, if any, for the DCC.   
The DCC will then record the DSMB report and disburse.  The DCC will forward reportable events 
to all FRIEND  investigators  and NIHCD. The Protocol PI [INVESTIGATOR_254230]. Site PIs 
will report the SAE to their site IRB according to local IRB requirements. For more information, 
please see the FRIEND /DSMB Communication Procedure.   
21 
 
FRIEND PK PRE -FRIEND PROTOCOL V. 2.1                                           
JUNE 29, 2021  
 7.4 Unanticipated Problems  
7.4.1 Definition of Unanticipated Problems (UP)  
The Office for Human Research Protections (OHRP) considers unanticipated problems involving 
risks to participants or others to include, in general, any incident, experience, or outcome that 
meets all of the following  criteria:  
 
• Unexpected in terms of nature, severity, or frequency given (a) the research procedures 
that are described in the protocol -related documents, such as the Institutional Review Board 
(IRB) -approved research protocol and informed consent document; and (b) the 
characteristics of the participant population being studied;  
• Related or possibly related to participation in the research (“possibly related” means there 
is a reasonable possibility that the incident, experience, or outcome may have b een caused 
by [CONTACT_3459]); and  
• Suggests that the research places participants or others at a greater risk of harm (including 
physical, psychological, economic, or social harm) than was previously known or 
recognized.  
7.4.2 Unanticipa ted Problem Reporting  
The investigator will report unanticipated problems (UPs) to the reviewing Institutional Review 
Board (IRB) and to the Data Coordinating Center (DCC)/lead principal investigator (PI). The UP 
report will include the following informati on: 
 
• Protocol identifying information: protocol title, PI’s name, and the IRB project number;  
• A detailed description of the event, incident, experience, or outcome;  
• An explanation of the basis for determining that the event, incident, experience, or outco me 
represents an UP;  
• A description of any changes to the protocol or other corrective actions that have been 
taken or are proposed in response to the UP.  
 
The following UPs require prompt reporting:  
• Breaches of confidentiality invol ving risks;  
• Data and Safety Monitoring Board (DSMB) reports an interim analysis altering the 
risk/benefit profile by [CONTACT_254263];  
• Protocol deviations, violations, or other accidental or unintentional changes to the protocol 
or procedures invol ving risks or with the potential  to recur;  
• Unapproved changes made to the research to eliminate an apparent immediate hazard to a 
subject;  
• Other problem or finding (e.g., loss of study data or forms) that an investigator or research 
staff member believes could  influence the safe conduct of the research.  
 
To satisfy the requirement for prompt reporting, UPs will be reported using the following timeline:   
 
• UPs that are serious adverse events (SAEs) or require prompt reporting will be reported to 
the IRB and to t he DCC/study sponsor according to the timel ine laid out for other SAEs in  
Table 2. 
22 
 
FRIEND PK PRE -FRIEND PROTOCOL V. 2.1                                           
JUNE 29, 2021  
 Any other UP will be reported to the IRB and to the DCC/study sponsor at time of continuing 
review of the investigator becoming aware of the problem.  
 
7.5 Data Collection and Management (including quality assurance/compliance 
measures)  
7.5.1 Data Entry and Forms  
Case Report Forms (CRFs) will be developed as the protocol is developed. All CRFs will be paper 
forms.  Site coordinators will be responsible for timely CRF completion and data entry of the CRFs 
into the designated electronic data entry (EDC) system. CRF completion should occur at the time 
of the visit. Lab results sections should be completed within two wee ks of results. Each site is 
asked to ensure that all data is entered into the EDC system within three weeks of the study visit.  
7.5.2 Data Security  
For security purposes, PHI, including patient names and addresses, will be locked and secured at 
the participating  sites, and data will be linked through a unique identification number, which will 
be assigned after a patient is screened or enrolled. Access will be limited to authorized individuals 
(21 CFR 11.10(d)).     
7.5.[ADDRESS_309170] Manager 
will review all signed and dated forms required by [CONTACT_1622] (such as financial disclosure forms), 
the curriculum vitae and certifications of the investigators and personnel, CRF training, and the 
written IRB ap proval of the protocol and consent form.   
The on -site monitor will return to the clinical site after a defined number of patients are recruited 
(can be as early as the recruitment of the 2nd patient) or a certain time period has passed, depending 
on the d uration of the protocol execution. The schedule of visits will be discussed and agreed upon 
by [CONTACT_254264].  
During the site visit, the clinical sites sho uld provide to the monitor a space and access to all 
relevant records including medical records and regulatory binders, and there would be immediate 
verbal feedback provided to the site after original source documents are compared to entries in the 
[ADDRESS_309171] the source doc uments, a review of all 
regulatory documents, a review of all informed consents, and a review of all pharmacy logs. The 
clinical site PI [INVESTIGATOR_254231]. The 
monitor will review electronic data from all sites, providing a method for identifying systematic 
errors or problems.  
To assure Good Clinical/Laboratory Practice,  the monitor will control adherence to the 
protocol at the clinical sites and evaluate the competence of the personnel at the clinical  sites 
including the ability to obtain written informed consents and record data correctly. The monitor 
will inform the DCC PI, the Steering Committee, and NICHD regarding problems relating to 
facilities, technical equipment, or medical staff. A thorough w ritten report will follow each site -
visit and will include a detailed itemization of discrepancies and items requiring follow -up or 
reconciliation. This report will also be forwarded to the Steering Committee for review. The 
monitor will be responsible for  maintaining regular contact [CONTACT_254265]. When the study ends, the monitor will also visit the clinical site to provide assistance for 
close -out. 
7.[ADDRESS_309172] (DSMB) will review and interpret data 
generated from the FRIEND  sites and to review protocols prior to their implementation.  Its 
primary objectives are to ensure the safety of study subjects, the integrity of the research data and 
to provide FRIEND  with advice on the ethical  and safe progression of the study . The DSMB 
advises on research design issues, data quality and analysis, and research participant protections 
for each prospective and on -going study.  A copy of the DSMB Charter can be found in the 
appendix.  
The DSMB members are appointed by [CONTACT_254266].  DSMB members are experts in and represent the following fields: 
biostatistics, epi[INVESTIGATOR_623], infertility, gynecology and ethics.  The DCC  Coordinator is 
responsible for scheduling regular committee meetings, recording all meeting minutes and 
summarizing the committee recommendations for the FRIEND consortium .  Steering Committee 
members are prohibited from attending closed sessions o f the DSMB.  Open sessions may be 
attended by [CONTACT_254267].   
7.8 Reporting  
Administrative Reports will be prepared by [CONTACT_15791], and they include monthly and quarterly 
reports to the FRIEND Collaborative group  on accrual, data quality and study compliance and 
reports presented in the packet produced for each Steering Committee and DSMB. Statistical 
reports include reports to the FRIEND Collaborative group  from the data analysis, and special 
reports for sci entific manuscripts.  
Statistical Reports will be generated in SAS. Reports are provided for DSMB reviews, and for 
final analysis of study results in preparation for scientific publications. The content of the interim 
reports will be very complete and will  serve as the template for the final report of each study, 
which in turn will form the basis of the publication of the results. Our proposed reports to the 
DSMB would include the following: a protocol description and history; accrual rates; site 
24 
 
FRIEND PK PRE -FRIEND PROTOCOL V. 2.1                                           
JUNE 29, 2021  
 performanc e in terms of accrual; eligibility; protocol violations; data accuracy and minority 
representation; patient characteristics by [CONTACT_254268]; and the rate of adverse experiences.  
7.[ADDRESS_309173], and the protocol and informed consent 
template, including future amendments, will be submitted to the sIRB. Protocol amendments and 
changes to the  consent forms will be distributed from the DCC via numbered memos. Approval 
documents and consents will be made available to the sites. Reporting local and study -wide 
adverse events wil l be done according to the sIRB Maintenance/Retention of site records . In order 
to comply with Good Clinical Practice (GCP) requirements, the investigators must maintain the 
master patient log that identifies all patients entered into the study for a period of two years after 
the study ends so that the subjects can be identi fied by [CONTACT_254269].  The PI [INVESTIGATOR_254232]’ files and other source data for a minimum of [ADDRESS_309174] 
Managers will work with NICHD colleagues in meeting all regulatory requirements 
includin g compliance with ICH and HIPAA requirements, FDA code for federal regulations 
(Title 21), and IND applications. For example, the DCC Project Managers will register this  
clinical trial in a timely manner with Clinica lTrials.gov  via a web -based data entry system called 
the Protocol Registration System (PRS).  
7.11 Protocol Amendments  
Given the scope of this trial, the protocol is not expected to be revised once the recruitment starts. 
However, if any changes do occur, Protocol amendments and changes to the consent forms will be 
distributed from the DCC via numbered memos. Approval docu ments and consents will be made 
available to the sites. Reporting local and study -wide adverse events will be done according to the 
sIRB.  
7.12 Overall Policy  
The publications policy proposes guidelines for publications that originate from our collaborative 
FRIE ND consortium .  Decisions concerning publications shall be determined by [CONTACT_21128] 
(majority vote) of the collaborating principal investigators (or designate) noted below as the 
"Consortium ". This policy is designed to promote prompt, exact, quality public ations and 
presentations of Network studies with appropriate academic recognition of those with significant 
contributions.  Protocols are classified into three types:  ‘Main Study’ (which may include major 
and minor publications), ‘Ancillary Study’, and ‘P ilot Study’.  Additionally, there may be 
publications from concepts or ideas generated by [CONTACT_254270]  (“Related Publications”) or from 
other groups utilizing FRIEND  data and/or specimens “Outside Studies” (those utilizing data 
and/or specimens from the FRIE ND studies).  Abstract submissions to national meetings will also 
follow the publications policy below. The progress of publications (including presentations) will 
be a standing agenda note on all phone conferences and meetings. The FRIEND consortium  will 
make the final disposition regarding disputes with respect to analysis request approval, 
prioritization, presentation, authorship and/or manuscript submission.  
25 
 
FRIEND PK PRE -FRIEND PROTOCOL V. 2.1                                           
JUNE 29, 2021  
 7.13 Main Study  
A Main Study is a consortium  study designed prospectively by [CONTACT_254271].  At the end of each Main Study, a primary analysis resulting in the primary 
manuscript and a number of secondary analyses is produced based on the research questions stated 
in the protocol.  The Protocol leader  is the primary author o f the primary analysis. A main study 
can generate major (related to the major hypotheses) and minor publications (relating to secondary 
hypotheses).  
7.13.1  Major Publications  
A major publication is defined as one reporting results of the major hypotheses tested.   (For 
example, does hMG/IUI increase cyclic fecundity in couples with unexplained or male factor 
infertility?).  
 
1. Authorship:   Publications will include the names of investigators from each FRIEND site  and 
the DCC.  Each FRIEND  and DCC will have up to t wo authors per publication, ordinarily the PI 
[INVESTIGATOR_79761] -PI, but this may at times involve another investigator who has contributed to the study 
at their site, in lieu of the PI [INVESTIGATOR_12749] -PI.  The principal investigator [INVESTIGATOR_254233].  No more than [ADDRESS_309175] Author:   The lead invest igator initiating the protocol will be the first author.  The first 
author would always be expected to prepare the initial draft of the manuscript. The author will 
prepare the first draft of the manuscript in a timely fashion after receiving  all the relevant data 
analyses from the DCC. The primary author will circulate the final draft to all authors prior to 
submission, with a timely turnaround of comments from other authors expected.  Final decision of 
the manuscript content will be determin ed by [CONTACT_97677] . In the event that the initiating 
protocol investigator declines first authorship or fails to meet the timeline determined by [CONTACT_254272]  
(as determined by [CONTACT_184472]) and monitored monthly, the next FRIEND  investigator in the 
rank order  of authors (described below) will be the first author.  
3. Authorship Order:   All authorships are expected to meet reasonable criteria as set forth by [CONTACT_19483]. Uniform requirements for manuscripts 
submitted to  biomedical journals. http://www.icmje.org . Updated February 2006. Accessed April 
4, 2007.  The overall authorship order will be 1) the primary author, 2) FRIEND  investigators, 3) 
a DCC investigator, additional outside investigators with a limit of one author per site, and end 
with the DCC  PI. 
 
Authorship 
Order 
Category  Description  
1 Lead Investigator of the Protocol (N =1)  
2 Primary FRIEND Investigators of the Protocol (N = 
6); DCC investigator (N = 1)  
3 Other  Investigators (N to be determined)  
4 DCC PI (N = 1)  
 
[ADDRESS_309176] 
recruitment, data accuracy and promp tness of data report according to the chart below:  
 
Investigative 
Sites  # Subjects 
Rank  Accuracy 
Rank  Total  
Rank  Authorship 
Order  
A 1 4 5 3 
B 2 7 9 6 
C 3 1 4 2 
D 4 2 6 4 
E 5 3 8 5 
F 6 5 11 7 
G 7 6 13 8 
 
Data accuracy will be ranked according to the rate of missing or false data entries/randomized 
subject at each site.  Inquires that show data was accurately entered will not count against this rate 
of data inaccuracy.  Each site’s PI [INVESTIGATOR_254234] t o the study 
of that site’s authors.  In the event the journal editor requires fewer authors even after written 
documentation of the authors’ contribution has been provided, the steering committee will vote on 
the authorship order which will include at a mi nimum the Lead Investigator and PI [INVESTIGATOR_108200] (or 
his/her designate) in the positions listed above. The other authors will be referenced in the footnote 
and listed in the title page.  
 
4. Acknowledgement Section:   The acknowledgement section will include ot her investigators and 
study personnel who contributed substantially to the study by [CONTACT_3725], as well as members of the  Data 
and Safety Monitoring Board.  The designation will list the initials of the individual followed by 
[CONTACT_254273] (e.g. C. L. Gna tuk, J.A. Ober, R.N., etc.) Significant contributions include but 
are not limited to protocol review, initiation and participation at each site, subject recruitment and 
enrollment, study conduct, data analysis, and preparation of the manuscript.   
7.13.[ADDRESS_309177] secondary 
hypotheses.  (One example would be testing whether metformin us e spares the dose of clomiphene 
resulting in lower dose needs.)  Ideas for "minor studies" will, in general, be proposed by a single 
individual, who would direct all efforts leading to publication and representation.  The results from 
minor studies would b e handled similarly to those from major studies.  The “Protocol” is defined 
as the Concept Protocol/study design of the hypothesis resulting in the publication.  
 
Authorship will follow the Major publications guidelines above with the exception that the 
individual leading the minor study would be the first author, followed by [CONTACT_254274][INVESTIGATOR_254235].  The Lead Investigator of the 
minor publication can propose additional investigators who contributed  to the study, whose 
inclusion in the authorship will be voted on by [CONTACT_254275]  (majority vote of the 
consortium  required for inclusion in authorship ).  Centers may wish to withdraw inclusion from 
authorship of publications of minor studies in w hich only data are contributed, and this will be the 
decision of the individual site PI.  
[ADDRESS_309178] be a need for collection of additional data not already collected in the Main Study.  An 
Ancillary Study may also be designed by [CONTACT_254276], who would serve as the 
lead investigator and pri mary author of the paper.  Ancillary Studies may be a “single -center” or 
“multi -center”.   
A “single -center” Ancillary Study is a study in which all data are collected, stored and analyzed at 
a single center.  The center bears the additional cost of such a  study.  The study requires approval 
of the FRIEND consortium .  The center conducting the study is responsible for the analysis and 
reporting of the results.  Abstracts and manuscripts resulting from data from the single -center 
Ancillary Study are not subj ect to the FRIEND Publications Policies.  
A “multi -center” Ancillary Study is defined as one for which data or material (such as specimens) 
are collected at more than one center, or additional funds for conduct of the study are provided by 
[CONTACT_254277] e DCC provides data analysis. Multi -center Ancillary Studies require the 
approval of the FRIEND consortium . 
Authorship will be as per Major publications above with the exception that the individual leading 
the ancillary study and writing the paper would be  the first author, followed by [CONTACT_254278], etc. A center not participating in the ancillary study would not receive 
authorship unless by [CONTACT_254279].  
7.13.[ADDRESS_309179] from an 
ancillary publication in that a related publication reports on a study, concept or new methodology 
that h as not been subjected to formal DSMB review and approval. Generally, “Related 
Publications” will arise from ideas and studies discussed with the FRIEND consortium , but not 
voted upon to become formal protocols.  
The investigator who initiates, conducts and  writes the study and those who (s)he names will be 
the sole authors. The authors should acknowledge the contribution of the FRIEND consortium  in 
the author line of the publication according to the format of the journal.   
7.13.5  Outside Studies  
Outside studies wi ll result from the sharing of data and/or specimens with investigators whose 
protocols have been approved by [CONTACT_181127], and who comply with all components of 
those policies. All publications will acknowledge the assistance of the FRIEND consor tium in 
making the database available on behalf of the project.  In addition, however, a disclaimer will 
need to be included stating, “the contents of this report represent the views of the authors and do 
not represent the views of the FRIEND consortium .”   
28 
 
FRIEND PK PRE -FRIEND PROTOCOL V. 2.1                                           
JUNE 29, 2021  
 7.13.6  Presentations   
FRIEND  data should be presented before national organizations by [CONTACT_254280], Ancillary, and Pi[INVESTIGATOR_7602].  Organizations that might be appropriate include the 
American Society of Reproductive Medicine, the Soc iety for Gynecologic Investigation, and  
the American College of Obstetricians and Gynecologists .  All presentations will be approved by 
[CONTACT_941] P & P committee.  Once data are published in at least abstract form, all members of the FRIEND  
consortium can cite them publicly in lectures.  
However, investigators should avoid citing specific numbers in review articles and chapters, for 
this could jeopardize peer review publication. Authorship, First Author, and Author Order are as 
described for Major Publications, and if there is an authorship limit to the abstract we will follow 
the plan above under Major Publications.  Oral and poster presentations, including those resulting 
from secondary analyses at professional societies, must list all authors and participating  
institutions.  
[ADDRESS_309180]: a pi[INVESTIGATOR_254236]. International journal 
of women's  health. 2013;5:[ADDRESS_309181] -Davis G, Montgomery -Rice V, Rajaratnam V, Al -Hendy A.  
Antiproliferative and proapoptotic effects of epi[INVESTIGATOR_254237]. Fertility 
and sterility. 2010;94(5):[ADDRESS_309182] inhibits proliferation of uterine leiomyoma cells in vitro and in nude mice. American 
journal of obstetrics  and gynecology. 2010;202(3):289.e1 -9. 
4.  Khan N, Mukhtar H. Tea polyphenols for health promotion. Life sciences. 2007;81(7):[ADDRESS_309183] inhibition of 
human leiomyoma cell proliferation is mediated via catechol -O-methyltran sferase. Gynecologic and 
obstetric investigation. 2014;78(2):109 -18. 
 
  
30 
 
FRIEND PK PRE -FRIEND PROTOCOL V. 2.1                                           
JUNE 29, 2021  
 9 Appendix J: Investigator Signature [CONTACT_254287]:    
 
Version :  
 
Principal Investigator:  
 
I, [Insert PI’s name] , the Principal Investigator [INVESTIGATOR_8178] [Insert Institute Name] , hereby [CONTACT_254281] I 
have read and agree to conduct this study in accordance with this protocol on behalf all FRIEND 
Investigators and research staff from my site.  
 
 
_______________________________ _____________  _________________  
Signature      [CONTACT_1782]  
 
  
31 
 
FRIEND PK PRE -FRIEND PROTOCOL V. 2.1                                           
JUNE 29, 2021  
 9 Appendix K: DSMB Charter  
 
 
DATA AND SAFETY MONITORING BOARD (DSMB) CHARTER  
 
Purpose and Responsibilities of the DSMB  
The members of the Data and Safety Monitoring Board (DSMB) identified in this Charter for the 
FRIEND study are responsible for safeguarding the interests of study participants, assessing the 
safety and efficacy of all study procedures, and shall monitor the overall conduct of the FRIEND 
trial.  This Committee will serve as an indepe ndent advisory group to the Director of NICHD, and 
is required to provide recommendations about starting, continuing, and stoppi[INVESTIGATOR_254238].   
 
This Committee is responsible for identifying mechanisms to complete various tasks that will 
impact the safety and efficacy of all study procedures, and overall conduct. The table below 
identifies the key areas where oversight is necessary and the ways in which the Committee for the 
FRIEND study will complete those tasks.  
 
Basic Responsibility of DSMB  Method  DSMB for FRIEND will use to complete task  
Familiarize themselves with the 
study protocol   Review study protocols and informed consent forms.  
Monitor adverse events   Adverse Event: Review quarterly progress reports 
prepared by [CONTACT_15791].  
 Serious Adverse Events: Review report submitted by 
[CONTACT_254282] -
threatening or fatal, or within two weeks otherwise.  
 The DSMB will submit a report of their review to the 
DCC Coordinator within 7 business days if the SAE 
is life-threatening or fatal, or within two weeks 
otherwise.  
Monitor data quality   Conduct interim evaluations of the data.  
Oversee participant recruitment 
and enrollment   Review interim progress reports prepared by [CONTACT_219001].  
Develop an understanding of the 
Study’s risks and benefits   Review study protocols and related literatures.  
 Review interim reports of subject accrual and 
outcome measures provided by [CONTACT_15791].  
 Assess the need to perform further in -depth 
evaluation of the benefits and risks of the study after 
reviewing each report.  
Ensure the proper reporting occurs   Review and approve the meeting and reporting 
schedule listed in Sections [ADDRESS_309184]  
 
Data Coordination Center (DCC)  
Hepi[INVESTIGATOR_254220], PhD, DCC Principal Investigator  
[INVESTIGATOR_254239], DCC Data Manager and Statistician  
 
Janet Sun, MS, Biostatistician  
Siobhan Thompson, MPH, Project Manager/Clinical Research Associate  
Donna DelBasso, DCC Sr. Administrative Assistant  
 
Lead Investigator(s)  
 
The Data Manager at the DCC will prepare the DSMB reports. The DCC Project Director will 
review all DSMB reports prior to submission to the DSMB. The DCC Data Manager will not be 
blind to treatment condition.  
 
DSMB Members, Organizational Chart, & Communications  
Members  
The DSMB for the FRIEND study is comprised of the members listed in the table below.  In 
addition, their high -level roles and  responsibilities are identified in the table.  
  
Name [CONTACT_254288] S. Guzick, 
M.D., Ph.D.  
 Chair of 
DSMB  
Voting 
member   Chair the DSMB discussion and prepare written 
recommendations to FRIEND.  
 Ensure the safety of study subjects, the integrity of 
the research data.  
 Provide FRIEND with advice on the ethical and 
safe progression of studies conducted.  
 Advises on research design issues, data quality and 
analysis, and research participant protection for 
each p rospective and on -going study.  
Peter S. Bernstein, 
MD, MPH  Voting 
member   Ensure the safety of study subjects, the integrity of 
the research data.  
 Provide FRIEND with advice on the ethical and 
safe progression of studies conducted.  
 Advises on research de sign issues, data quality and 
analysis, and research participant protection for 
each prospective and on -going study.  
 Katherine Burns, 
Ph.D.  Voting 
member  
Robert W. Rebar, 
M.D.  Voting 
member  
Ming T. Tan, Ph.D.  
 Voting 
member  
Kimberly L. 
Thornton, M.D.  Voting 
member  
 
[ADDRESS_309185] (COI) and provid e their signed summary of any 
COI for the study, at its onset, to the DCC. A table summarizing any COI within the DSMB is 
provided in the Appendix.  
 
Prior to each meeting, all members of the FRIEND DSMB will have an opportunity to state 
whether they have developed any new conflicts of interest since the meeting. As a new COI is 
identified it must be documented in the table in the Appendix and a new signed summary of the 
COI should be provided to the DCC for record -keepi[INVESTIGATOR_24069].  
 
If a new conflict is re ported, the DCC will determine if the conflict limits the ability of the DSMB 
member to participate in the discussion.  
 
All DSMB members will be compensated for their role in supporting the committee. 
Compensation will include an honorarium for meeting att endance and any travel costs.  
 
Meeting Schedule  
DSMB meetings will be conducted quarterly. However, the DSMB may hold a meeting at any 
time in accordance with their mission.  
 
Report Schedule and Content  
The type of reports (full or brief) is indicated bel ow, followed by a description of the contents of 
each type.  
 
DSMB Report  Report Submission Date  Type of Report  
1.  Brief  
2.  Brief  
3.  Full 
4.  Brief  
5.  Full 
6.  Brief  
7.  Full 
8.  Brief  
 
Brief DSMB reports  will include the following summaries:  
• overall actual versus projected enrollment accrual  
• overall randomization update  
• overall study drop -out rate  
• serious adverse events  
34 
 
FRIEND PK PRE -FRIEND PROTOCOL V. 2.1                                           
JUNE 29, 2021  
 • primary outcome measures update  
 
Full DSMB reports  will include the following summarie s: 
• recruitment update (number screened) overall and by [CONTACT_3725]  
• enrollment update (enrolled defined as randomized to a treatment) overall and by [CONTACT_3725]  
• accrual status including actual enrollment compared to projections overall and by [CONTACT_3725]  
• randomization update (i .e., number assigned to each treatment arm)  
• study drop -out rate for enrolled patients (number, reason, time point) overall and by [CONTACT_3725])  
• pre-specified subset of baseline demographic data for enrolled patients  
• safety data, adverse events, and serious adverse  events  
• number of case report forms expected  
• number/percentage of expected case report forms received – overall and by [CONTACT_3725]  
• number of case report forms that are query clean  
• primary outcome measures update  
 
Efficacy Outcome Summary  
An interim analysis is planned at the mid -point of the study to assess the overall pregnancy rate 
(i.e., the three groups combined) while maintaining blinding of treatment assignment in order to 
assess whether this pregnancy rate approximates the predicted rate of 30 -40%, and whether 
additional subjects may be needed to meet power targets.  Since treatment assignments will not be 
identified, it is not thought that adjustments in significance levels will be required.  
 
 
Appendix:  Summary of COI within the DSMB  
 
 
DSMB M ember Name  [CONTACT_254289] a COI 
Identified?  Will the Member Remain 
Part of the Committee?  
    
    
    
    
    
    
 
  
[ADDRESS_309186] Statement  
 
 
I, ______________________, assuming the role of _____________________________      
            
 (insert role, for example: DSMB member)  
 
for the __________________________________________________________  
      (insert project or study name)  
 
agree to the following statements.    
 
□ I agree to:  
▪ protect the interests and safety of study participants;  
▪ uphold the integrity of the research process including data collection and analysis to be 
as free from bias and preconception as I am able;  
▪ adhere to the highest  scientific and ethical standards, to comply with all relevant 
regulations and to eliminate or disclose, during my involvement with the proposed 
clinical research project, any real or apparent conflicts of interest.  
 
In addition:  
 
□ I declare that I, my sp ouse or dependent children, or organization with which I am connected, 
do/does not have any financial interest in the ___________________ study, where financial 
interested is defined by [CONTACT_254283], as anything of monetary value, including but not limited to,  
salary or other payments for services (for example, consulting fees or honoraria); equity interests 
(for example, stocks, stock options or other ownership interests); and intellectual property rights 
(for example, patents, copyrights and royalties from su ch rights).   
The financial interest term does not include various items which can be found in The Federal 
regulation, PHS, DHHS Part 50 --Policies of General Applicability; Subpart F - Responsibility of 
Applicants for Promoting Objectivity in Research for W hich PHS Funding Is Sought.  
For Federal employees, financial interests that are allowable and require disclosure are:  
 
Financial Interest Disclosure : Financial interest that require disclosure are stock holdings in 
pharmaceutical firms, medical device man ufacturers, and biotechnology companies  
Allowable Financial Interests : In a company that produces a product that is being evaluated by a 
study, participants may hold up to $15,000 of stock: and, up to an aggregate of $25,000 of the 
stock of that company an d its competitors who produce that (or a similar) product. As an alternative 
to individual stock holdings, participants may hold up to an aggregate of $50,000 in sector mutual 
funds -including pharmaceutical/health care sectors.  

[ADDRESS_309187] exists, could lead to the need to withdraw 
from the study.  
 
□ I agree to not withhold any data related to the _____________________ study or to interfere 
with the analysis or publication of the study’s results.  
 
□ I will not engage in activities that could be viewed as real or apparent COI, including but not 
limited to:  
 
□ having a part -time, full -time, paid, or unpaid employee status of any organizations that 
are: (a) involved in the study under review; (b) whose products will be used or tested in the 
study under review , or whose products or services would be directly and predictably 
affected in a major way by [CONTACT_58435];  
 
□ being an officer, member, owner, trustee, director, expert advisor, or consultant of such 
organizations;  
 
□ being a current collabora tor or associate of the principal investigator (applicable to 
potential members of data safety and monitoring boards);  
 
□ having a scientific interest beyond that required for my role, where scientific interest is 
defined as having influence over the proto col, the study design, conducting the study 
analysis or any reporting related to the investigation (applicable to potential members of 
data safety and monitoring boards).  
  
[ADDRESS_309188] (DSMB)  
Confidentiality Agreement  
 
I agree to serve  as a DSMB member for the FRIEND (Reproductive Medicine Collaborative 
Consortium: a randomized placebo -controlled trial of EGCG to improve fertility in women 
with uterine fibroids) consortium for which Yale University Collaborative Center for 
Statistics in  Science serves as the Data Coordination Center (DCC).  
As a DSMB member I understand that I will be provided with and have access to documents 
submitted by [CONTACT_254284], Registries or other 
consortium -related mate rials, including proprietary and confidential information.  
I shall not disclose any confidential information (oral or written) unless required to do so by 
[CONTACT_2371].  Confidential documents may be distributed to an administrative assistant, who is not 
permitted  to share the materials with anyone other than me.  
I agree that I will not distribute or publish the study records.  I further agree that I shall not 
make use of consortium materials except for the express purpose of advising the Consortia 
and the NICHD.  
I have read this agreement and agree to abide by [CONTACT_120830].  
 
Name (Print or Type): ___________________________________________________  
 
Signature: ________________________________________ Date: _______________  
 
 
 
 
 
 
 
 
 
 
 